Cargando…
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibrobla...
Autores principales: | Puengel, Tobias, Lefere, Sander, Hundertmark, Jana, Kohlhepp, Marlene, Penners, Christian, Van de Velde, Frederique, Lapauw, Bruno, Hoorens, Anne, Devisscher, Lindsey, Geerts, Anja, Boehm, Stephanie, Zhao, Qihong, Krupinski, John, Charles, Edgar D., Zinker, Bradley, Tacke, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224277/ https://www.ncbi.nlm.nih.gov/pubmed/35743140 http://dx.doi.org/10.3390/ijms23126696 |
Ejemplares similares
-
Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
por: Puengel, Tobias, et al.
Publicado: (2017) -
Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion
por: Bartneck, Matthias, et al.
Publicado: (2020) -
The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2020) -
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands
por: Korbecki, Jan, et al.
Publicado: (2020) -
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022)